Table 1 from T-Cell Receptor and Immune Gene Expression Pharmacodynamics for Durvalumab Alone and with Tremelimumab or Bevacizumab in Unresectable Hepatocellular Carcinoma
收藏数据链接：
官方服务：
资源简介：
Overview of response or T-cell clonality in clinically evaluable participants, RNA-seq–evaluable participants, and immunoSEQ-evaluable participants.
创建时间：
2026-02-17
